
    
      This trial is divided into three parts: 1) The first part: Four Chinese healthy subjects will
      be included in the pre-test group to evaluate the safety, tolerability and pharmacokinetics
      after taking SYHA1805 tablets; 2) The second part: To evaluate the safety, tolerability,
      pharmacokinetics and pharmacodynamic characteristics, several single ascending doses of
      SYHA1805 tablets or matching placebo tablets will be randomly administered to 24 Chinese
      healthy subjects under fasting condition; 3) The third part :To evaluate the food effect on
      the pharmacokinetic characteristics, a single dose SYHA1805 tablets will be administered to
      12 Chinese healthy subjects under fed or fasted condition.
    
  